Lilly reshuffles its executive committee as the obesity business scales

Eli Lilly announced a set of executive leadership changes on May 8, 2025, shifting three senior leaders into new roles as the company prepares for simultaneous launches of an obesity pill and a next-generation injectable ^[1]. The company said the moves are meant to sharpen its focus on the US business and on global therapeutic areas as growth continues in its cardiometabolic health division ^[1].

Under the changes, Ilya Yuffa, who had led Lilly International, will become executive vice president and president of Lilly USA and Global Customer Capabilities. He will oversee sales, marketing, and commercial strategy for all US products, including the rollout of upcoming launches ^[1][3]. Patrik Jonsson, who had led Lilly's Cardiometabolic Health unit and served as president of Lilly USA, will move to lead Lilly International, taking charge of all markets outside the United States ^[1][3]. Kenneth Custer, a 16-year Lilly veteran who most recently ran Lilly Canada, will be promoted to executive vice president and president of Lilly Cardiometabolic Health and will join Lilly's executive committee ^[1][3]. Custer previously worked on early development of tirzepatide, the molecule sold as Mounjaro and Zepbound ^[1].

Lilly's CEO David Ricks credited Jonsson with driving growth in the cardiometabolic and US businesses and said the reshuffle is meant to help the company "reach the next level" ^[1]. The announcement came about a week after Lilly reported first-quarter 2025 results showing revenue up 45%, driven by Mounjaro and Zepbound sales, with the company reaffirming full-year revenue guidance of $58 billion to $60 billion ^[2]. It also followed news in mid-April that Lilly's experimental oral GLP-1 drug, orforglipron, showed a safety profile similar to injectable GLP-1 medicines already on the market in its first Phase 3 trial, called ACHIEVE-1, with patients losing an average of 16 pounds ^[2].

Why it matters for patients

This is a corporate leadership change, not a change to any approved drug, dose, or price. Orforglipron, which Lilly is developing as a once-daily pill, has not been approved and remains in testing; ACHIEVE-1 was only the first of seven planned late-stage studies in diabetes and obesity, with more data expected later in 2025 ^[2]. Nothing in these sources indicates a change to current supply, insurance coverage, or price for Mounjaro, Zepbound, or any other Lilly product.

That said, the reorganization signals how Lilly is positioning its commercial operations ahead of possible new product launches. By putting one executive in charge of all US commercial activity, including the launch of new products, the company is centralizing decisions that could affect how quickly a new pill or injectable reaches pharmacies and how it is marketed to patients and doctors, if and when it is approved ^[1]. For patients currently on tirzepatide or watching for new options, the reshuffle suggests Lilly expects the obesity drug market to keep expanding and wants its US business built to handle it, though the sources do not describe specific plans for pricing, access programs, or manufacturing timelines tied to these leadership changes.

It is not yet known from these sources exactly when orforglipron might be submitted for FDA review or approved, or what its price or coverage status might be. The sources also do not detail whether these executive changes will affect coverage, out-of-pocket costs, or availability of Mounjaro or Zepbound in the near term.

What happens next

Lilly has said additional Phase 3 data readouts for orforglipron are expected later in 2025, following the April 17, 2025 ACHIEVE-1 results ^[2]. The company's next financial disclosures, expected later in 2025, would likely offer more detail on how the new executive structure is functioning and on the status of any application for regulatory approval of orforglipron. No specific approval or launch date is confirmed in these sources.